CASI Pharmaceuticals, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how CASI Pharmaceuticals performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

CASI Pharmaceuticals brings innovative cancer and disease treatments to the Chinese market. They act as a bridge, licensing drugs from global partners and navigating regulations to reach patients. This year, the company focused on "transition and consolidation." They are streamlining their business by selling off their China subsidiary to simplify their structure and reduce the high cost of maintaining a large commercial team.

2. Financial performance

CASI is currently in a growth phase where they spend more on research and operations than they earn from drug sales. Because they are not yet profitable, they rely on private investments and loans to fund their activities. For the year ending December 31, 2024, the company reported a loss of $25.7 million, which is an improvement over the $34.5 million loss in 2023. As of the end of 2025, they had 20,555,873 shares outstanding.

3. Major wins and challenges

• Wins: The company successfully managed complex licensing agreements and secured funding, such as a private investment round in July 2024. They are actively working to become a leaner, more focused business.
• Challenges: The company faces a "going concern" warning, which indicates that their recurring losses create uncertainty regarding their ability to continue operations without additional capital. They are also involved in legal disputes with partners like Juventas and Acrotech, which creates uncertainty regarding the future of their key drug portfolio.

4. Financial health

CASI depends on outside funding to sustain operations. While they do not carry heavy bank debt, they require consistent cash injections to maintain their business. As of December 31, 2024, they held approximately $8.5 million in cash. Their financial stability depends on successfully selling assets, securing new partnerships, or raising additional capital.

5. Key risks

• Going Concern: Recurring losses raise doubts about the company's long-term survival and its ability to meet financial obligations.
• Legal Disputes: Ongoing arbitration with partners could jeopardize access to essential drugs or result in significant financial penalties.
• Regulatory Environment: Operating in China requires navigating complex healthcare rules. If their drugs are not included on the National Reimbursement Drug List, their sales potential may be limited.
• Dilution: The company frequently issues new shares or debt to raise capital, which can reduce the ownership percentage of existing shareholders.

6. Future outlook

The company’s future is tied to the sale of their China subsidiary. A successful sale could provide the necessary cash to stabilize the business and allow them to focus on their remaining drug pipeline. If this sale does not close, the company will face significant challenges in addressing its cash requirements.

Investor Note: When considering an investment in a company at this stage, it is helpful to weigh the potential of their drug pipeline against the risks associated with their current cash position and ongoing legal matters. Always consider whether the company's strategy for becoming a leaner organization aligns with your personal risk tolerance.